Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $12.24 USD
Change Today -0.04 / -0.33%
Volume 469.8K
FOLD On Other Exchanges
As of 1:38 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/15 - $13.20
52 Week Low
06/2/14 - $2.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs include next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has completed two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson's disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

97 Employees
Last Reported Date: 03/3/15
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $1.1M
President and Chief Operating Officer
Total Annual Compensation: $635.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $568.6K
Chief Medical Officer
Total Annual Compensation: $707.1K
Vice President of Legal & Intellectual Proper...
Total Annual Compensation: $418.2K
Compensation as of Fiscal Year 2014.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc. Report Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Cash Flow Guidance for the Year 2015

Amicus Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $24,058,000 compared to $15,621,000 a year ago. Net loss was $24,288,000 compared to $15,943,000 a year ago. Net loss was $0.25 per basic and diluted share compared to $0.25 per basic and diluted share a year ago. The company now expects full-year 2015 net cash spend between $100 million and $110 million, up from the previous guidance range of $73 million to $83 million. The current cash position is projected to fund operations into the second half of 2016.

Amicus Therapeutics, Inc. to Report Q1, 2015 Results on May 05, 2015

Amicus Therapeutics, Inc. announced that they will report Q1, 2015 results on May 05, 2015

Amicus Therapeutics, Inc., Q1 2015 Earnings Call, May 05, 2015

Amicus Therapeutics, Inc., Q1 2015 Earnings Call, May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $12.24 USD -0.04

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies

Industry Analysis


Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,534.6x
Price/Book 11.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,333.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at